The Ipamorelin research, organized — mechanism, the gut, and the trial that didn't land.

The short version

The Ipamorelin research splits cleanly into three buckets. First, mechanism: it switches on the ghrelin receptor (GHS-R1a) and releases a burst of growth hormone without the cortisol-and-prolactin spillover of older peptides ^[1]. Second, the gut: because that same receptor sits on the nerves controlling gastric motility (how fast the stomach empties and the bowel moves), animal studies showed it speeds gut transit ^[9][10]. Third, the human reality check: one trial tested it for restarting the gut after surgery and missed its primary goal ^[3].

Below, each finding has its own heading and its own citation, including the animal numbers, the two-hour human half-life, and a frank look at the popular ipamorelin cjc-1295 pairing. Doses appear only as what was given in those studies, to those animals or trial subjects — never as a recommendation for anyone.

Mechanism: one clean job

Ipamorelin's founding study is still its most important. In rat pituitary cells, anaesthetized rats, and conscious pigs, it released growth hormone potently — in pigs its half-maximal dose was about 2.3 nmol/kg, comparable to GHRP-6's 3.9 nmol/kg ^[1]. The headline wasn't the potency, though. It was the selectivity: even at doses more than 200 times the GH dose, it didn't raise ACTH or cortisol above the level seen with normal GHRH ^[1]. That made it the first growth hormone secretagogue you could call "clean" — it does the GH job without dragging the stress-hormone axis along.

The receptor it hits, GHS-R1a, is the same one the hunger hormone ghrelin uses. Activate it on pituitary cells and you get GH; activate it on gut and vagal nerves and you get motility ^[11]. That dual location is why one molecule shows up in both the bodybuilding conversation and the gastroenterology literature. Interestingly, in fish pituitary cells ipamorelin released GH without changing GH gene activity at all — meaning the receptor works at the level of secretion, releasing pre-made hormone, not at the level of making more ^[14]. Ipamorelin can even ramp up the body's own ghrelin gene, a feedback loop seen in seabream ^[15].

Gut motility: the lead finding

This is the thread this site leads with, and it's the best-developed animal story. In a rat model of postoperative ileus (the stalled gut after surgery), repeated IV ipamorelin — 0.1 or 1 mg/kg, four times a day — significantly raised cumulative stool output, food intake, and body-weight gain over 48 hours versus vehicle, and a single dose shortened the time to first bowel movement ^[9].

A second rat study zeroed in on the stomach itself. IV ipamorelin at 0.014 and 0.14 micromol/kg significantly sped up gastric emptying in a surgical ileus model, pulling gastric retention back toward normal, through a ghrelin-receptor-and-cholinergic-nerve mechanism confirmed in cells at around 1 microM ^[10]. The broader reviews of ghrelin's "prokinetic" (gut-speeding) actions place these findings in context: as a class, ghrelin-receptor agonists accelerate gastric emptying ^[11], and more clinically advanced cousins like relamorelin (RM-131) have pushed the same mechanism further in GI development — RM-131 is reported to be hundreds of times more potent than the earlier clinical ghrelin mimetics, the class that includes ipamorelin ^[7][8].

Is ipamorelin FDA approved?

No. Ipamorelin is not FDA approved for anything. It was investigated — most notably for postoperative ileus (trial NCT00672074) — but never approved, anywhere, by any regulator. In 2024 the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk-substances list and reviewed it at the October 29, 2024 Pharmacy Compounding Advisory Committee meeting, tightening compounding-pharmacy access. It's sold only as a research chemical, and it's also banned in sport at all times under the WADA list (category S2) as a growth hormone secretagogue.

The one human trial — and why it matters

The defining human study is also the deflating one. In the only published Phase 2 RCT (NCT00672074), 114 adults recovering from bowel resection got 0.03 mg/kg IV twice daily for up to 7 days. The result: it missed its primary endpoint. Median time to first tolerated meal was 25.3 hours on ipamorelin versus 32.6 hours on placebo — a difference that didn't reach statistical significance (p=0.15) ^[3]. On the upside, there was no ipamorelin-specific safety signal in that short window: treatment-emergent adverse events hit 87.5% of the ipamorelin arm versus 94.8% of placebo ^[3].

So does cjc-1295 ipamorelin work? For the one thing ipamorelin was rigorously tested on, the trial says "not proven." Everything else — sleep, recovery, body composition, the popular CJC-1295 stack — rests on mechanism and short animal studies, not on controlled human outcomes ^[2][3]. The early human PK study did confirm the pharmacology is real and orderly: dose-proportional kinetics, a roughly two-hour half-life, and a single GH pulse peaking about 40 minutes after dosing ^[2]. Real pharmacology, unproven benefits — both things are true at once.

Ipamorelin cjc-1295

The most-searched ipamorelin topic isn't ipamorelin alone — it's the ipamorelin cjc-1295 pairing. The logic is mechanistic and genuinely elegant: ipamorelin hits the ghrelin receptor, while CJC-1295 is a long-acting GHRH analog that hits a different receptor (the GHRH receptor). Two different doors to the same room, pushed together, should produce a bigger, more natural GH release than either alone. That's the theory.

The evidence for the partner is solid on its own terms: CJC-1295, given once under the skin to healthy adults, produced dose-dependent GH increases of 2- to 10-fold for more than six days and 1.5- to 3-fold sustained IGF-1 elevation, while keeping GH pulsatile [referenced in the corpus on CJC-1295, not ipamorelin]. But — and this is the whole point — there is no published trial of the combination for any outcome. The stack is single-agent pharmacology bolted together by community practice, not a studied therapy.

Ipamorelin vs sermorelin

Ipamorelin vs sermorelin is a comparison of two different mechanisms, not two versions of one thing. Ipamorelin is a GHRP — a ghrelin-receptor agonist that mimics the hunger hormone to trigger GH ^[1]. Sermorelin is a GHRH analog — it copies the body's own growth-hormone-releasing hormone and works through the GHRH receptor instead. Sermorelin also has a regulatory history ipamorelin lacks. The reason people pair a GHRP like ipamorelin with a GHRH-type compound is exactly because the two routes are complementary: different receptors, additive GH release ^[1].

Ipamorelin vs tesamorelin

Ipamorelin vs tesamorelin is, again, GHRP versus GHRH analog. Tesamorelin is a stabilized GHRH analog with an actual approved human indication (HIV-associated excess abdominal fat) and a real human evidence base behind that use. Ipamorelin, the ghrelin-receptor peptide, has none — one failed Phase 2 trial and no approval ^[3]. They share the goal of raising growth hormone but arrive by different receptors, and they sit on opposite ends of the evidence spectrum: tesamorelin with an approved indication, ipamorelin with research-only status.